Reach: RWE Retrospektivní studie za účelem vyhodnocení dopadu cenobamátu na využití zdrojů zdravotní péče
Retrospektivní hodnocení využití zdravotnických zdrojů Cenobamate (HCRU) při řízení nekontrolovaných záchvatů fokálního počátku- retrospektivní studie přezkumu grafu
The Study is an observational, retrospective study which aim is to assess cenobamate's healthcare resources utilization (HCRU) in the management of uncontrolled focal onset seizures. The amin objective is to compare the resource utilization before and after the use of cenobamate. Data from medical charts will be used and inserted into the eCRF from which the analyses will be conducted. Data from 200 patients from 10 sites in 5 countries are included.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Kontakty a umístění
Studijní místa
-
-
Netherlands
-
Heeze, Netherlands, Holandsko
- Kempenhaeghe - Academisch Centrum voor Epilepsie
-
-
-
-
Germany
-
Freiburg im Breisgau, Germany, Německo
- Epilepsiezentrums am Neurozentrum des Universitätsklinikum Freiburg
-
Hamburg, Germany, Německo
- Epileptologicum
-
Kork, Germany, Německo
- Diakonie Kork, Epilepsiezentrum
-
-
-
-
UK
-
Glasgow, UK, Spojené království
- Institute of Neurosciences NHS Greater Glasgow and Clyde
-
Wolverhampton, UK, Spojené království
- Epilepsies - The Royal Wolverhampton NHS Trust
-
-
-
-
Spain
-
Barcelona, Spain, Španělsko
- Epilepsy Unit - Neurology Department Valle de Hebron Hospital
-
Madrid, Spain, Španělsko
- Epilepsy Unit of the Neurology Department of the Hospital Clínico San Carlos
-
Valencia, Spain, Španělsko
- Consorcio Hosp. General Universitario Valencia
-
-
-
-
Switzerland
-
Zurich, Switzerland, Švýcarsko
- Department of Neurology, University Hospital Zurich
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Adult patients affected by epilepsy with focal-onset seizures not adequately controlled after 2 or more anti-seizure medications (ASMs), due to efficacy or tolerability issues, who start a treatment with cenobamate as an adjunctive therapy (according to SmPC), in real world setting, and have at least 6 months of data on treatment and healthcare resources utilization (HCRU) (if any) prior to cenobamate starting date.
Popis
Inclusion Criteria:
- Male and female patients of any ethnic origin ≥18 years old at index date;
- Patients with a diagnosis of epilepsy with uncontrolled focal-onset seizures despite the previous treatment with from 2 to 5 ASMs who started treatment with cenobamate at index date;
- Patients presenting at least 1 seizure a month in the last 6 months prior to index date;
- Patients with at least 6 months of data coverage in the medical records prior to the index date;
- Patients with at least 12 months of data in the medical records after index date (with a maximum interval between data of 6 months).
- Patients who give the consent to the processing of personal data according to the General Data Protection Regulation (GDPR) and/or other applicable local regulation.
Exclusion Criteria:
- Patients who meet any of the contraindications to the administration of adjunctive ASMs according to their approved SmPC;
- Patients who started cenobamate within an EAP;
- Progressive neurological disease, including degenerative CNS diseases and/or progressive brain tumors;
- Patients with specific syndrome (e.g. LGS and Dravet);
- Pregnancy or lactation;
- Patients without self-judgement ability;
- Patients with substance and alcohol abuse or dependence (except for caffeine and nicotine);
- Patients participating in any pharmacological or nonpharmacological interventional study starting from 6 months before the index date.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: RETROSPECTIVE
Počet skupin / kohort
Kohorty a intervence
Skupina / kohortaSkupina / kohorta |
|---|
|
Adult patients affected by epilepsy with focal-onset seizures
Adult patients affected by epilepsy with focal-onset seizures not adequately controlled after 2 or more ASMs (anti-seizure medications), due to efficacy or tolerability issues, who start a treatment with cenobamate as an adjunctive therapy (according to SmPC), in real world setting, and have at least 6 months of data on treatment and HCRU (if any) prior to cenobamate starting date. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.
Časové okno: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU, will be collected the number of epilepsy/epilepsy treatment-related hospitalizations during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.
Časové okno: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU,will be collected the length of epilepsy/epilepsy treatment-related hospitalizations during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines
Časové okno: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU will be collected the number of epilepsy/epilepsy treatment-related outpatient visits (OP) during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines
Časové okno: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU will be collected the number of epilepsy/epilepsy treatment-related emergency room (ER) visits; |
0-12 months
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Časové okno: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Switch/add-on of other ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Časové okno: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Changes in the dose of co-ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Časové okno: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Changes in the number of co-ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Časové okno: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Time to discontinuation of ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related emergency and medical care
Časové okno: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on epilepsy-related emergency and medical care, the number of epilepsy/epilepsy treatment related emergency care, ambulance use, the number of outpatient visits with neurologists, and the number of epilepsy specialist nurses' intervention will be collected; |
0-12 months
|
|
Effectiveness of cenobamate used as adjunctive therapy
Časové okno: 0-12 months
|
To evaluate the effectiveness of cenobamate used as adjunctive therapy, seizure frequency at baseline and at routinely scheduled follow-up visits, till the end of observation will be collected. For comparability, seizure frequency will be extrapolated per month (28 days); |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related surgery
Časové okno: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related surgery the following data will be collected:
|
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on comorbidity-related healthcare resources utilization (HCRU)
Časové okno: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on comorbidity-related HCRU, the following data will be collected:
|
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on phone calls/virtual interventions
Časové okno: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on phone calls/virtual interventions, the number of phone calls/virtual interventions will be collected. |
0-12 months
|
|
Safety of cenobamate used as adjunctive therapy
Časové okno: 0-12 months
|
To evaluate safety of cenobamate used as adjunctive therapy, the number, type and severity of, adverse events, adverse drug reactions will be collected. Moreover, changes in the number, type, dose of concomitant medications other than anti-seizure medications will be collected over the duration of the study. |
0-12 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- 169(A)AV23432
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .